Nicox SA (FR:ALCOX) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nicox SA has announced the completion of patient recruitment in the U.S. for the Denali Phase 3 trial of NCX 470, a treatment for open-angle glaucoma or ocular hypertension. The trial, which is also ongoing in China, has met its primary efficacy analysis and demonstrated the drug’s superiority at certain timepoints compared to latanoprost. With more than 95% of the target patient number already randomized, Nicox anticipates releasing topline results by the second half of 2025 and submitting a New Drug Application in the U.S. by the first half of 2026.
For further insights into FR:ALCOX stock, check out TipRanks’ Stock Analysis page.